Chronic Lymphocytic Leukemia

This page contains recent news articles, when available, and an overview of Chronic Lymphocytic Leukemia but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Chronic Lymphocytic Leukemia

NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options  -  23 Nov 2009
PR Newswire (press release)Ofatumumab was added to the NCCN Guidelines as a treatment option for relapsed/refractory disease in patients with chronic lymphocytic leukemia (CLL), ...

Range of Cancer-Fighting Agents Get FDA Nod  -  23 Nov 2009
Oncology Nursing NewsArzerra (ofatumumab) has been approved for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of ...

Genentech, Biogen Idec Gets Complete Response From FDA For Rituxan For Chronic ...  -  ‎Nov 18, 2009‎
RTT NewsRituxan plus fludarabine and cyclophosphamide for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia. ...

Kareem Abdul-Jabbar gets leukemia: What you need to know  -  ‎Nov 10, 2009‎
Food ConsumerChronic lymphocytic leukemia (CLL): CLL affects lymphoid cells and usually grows slowly. It accounts for more than 15000 new cases of leukemia each year. ...

FDA Approves New Treatment for Chronic Lymphocytic Leukemia  -  ‎Nov 21, 2009‎
Linex Legal (registration)The US Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of ...

Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia ...  -  ‎Nov 18, 2009‎
7thSpace Interactive (press release)Here, we describe selective eradication of a putative precursor population in a patient with B-cell chronic lymphocytic leukemia, followed 6 months later by ...

Medical Edge: More effective treatments available for lymphocytic leukemia  -  ‎Nov 16, 2009‎
Post-BulletinDEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. ...

Newer, More Effective Treatments Are Available for Those With Chronic ...  -  ‎Nov 12, 2009‎
KFSMDEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. ...

Facet Biotech Announces Four Presentations at American Society of Hematology ...  -  ‎Nov 19, 2009‎
CNNMoney.com (press release)...(TruADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. ...

Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia  -  ‎Nov 2, 2009‎
Cancer Consultants...for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). ...

Primer on cancer types  -  ‎Nov 19, 2009‎
Gainesville SunThere is chronic lymphocytic leukemia, or CLL. People diagnosed with this type of leukemia are usually over the age of 55, and it almost never affects ...

Lonza steps up for GSK and Genmab  -  ‎Nov 11, 2009‎
FiercePharma ManufacturingAccording to Lonza, Arzerra treats chronic lymphocytic leukemia by alerting the immune system to protect B-cells, which become cancerous as a result of the ...

Biogen's Rituxan Label Expansion Delayed  -  ‎Nov 20, 2009‎
Zacks.com...of Rituxan (rituximab) plus fludarabine and cyclophosphamide (FC) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL). ...

Researchers Discover Antibody Receptor Identity, Propose Renaming Immune ...  -  ‎Nov 18, 2009‎
Science Daily (press release)To identify the true FCMR gene, the UAB researchers used chronic lymphocytic leukemia cells as a source of this gene, since such leukemia cells are known to ...

Business news in brief  -  ‎Oct 28, 2009‎
Philadelphia InquirerPaul Schweizer GlaxoSmithKline PLC received Food and Drug Administration approval for its drug Arzerra to treat chronic lymphocytic leukemia, ...

Swiss stocks - Factors to watch on Nov 19  -  ‎Nov 18, 2009‎
ReutersO) received a complete response from America's Food and Drug Administration (FDA) for Rituxan for chronic lymphocytic leukemia on Wednesday and said they ...

BioCryst $49M Public Offering Cashes in on Stock Momentum  -  ‎Nov 20, 2009‎
BioWorld OnlineData are expected in the first half of 2010. A separate Phase II trial is under way in chronic lymphocytic leukemia.

Irish researchers discover drug that can kill leukemia cells  -  ‎Nov 3, 2009‎
Irish CentralThe Irish Cancer Society funded the research project and tests show that while the new drug kills chronic lymphocytic leukemia, it does no harm to normal ...

Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 ...  -  ‎Nov 5, 2009‎
Reuters...commercialization of TRU-016, a CD37-directed product candidate in phase 1 clinical development for the treatment of chronic lymphocytic leukemia (CLL). ...

Lonza Successfully Develops A Manufacturing Process For Arzerra  -  ‎Nov 16, 2009‎
Pharmaceutical Online (press release)Lonza announces that GlaxoSmithKline (GSK) and Genmab's antibody Arzerra, which has just been approved for use in patients with chronic lymphocytic leukemia ...

Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product ...  -  ‎Nov 11, 2009‎
CNNMoney.com (press release)...will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), ...

Benefits application simplified for Vietnam veterans  -  ‎Nov 9, 2009‎
Stanly News & PressAL Amyloidosis, Chloracne, Chronic Lymphocytic Leukemia, Diabetes Mellitus (Type 2), Hodgkin's Disease, Multiple Myeloma, Non-Hodgkin's Lymphoma, ...

Micromet Axes Alliance with MedImmune Regaining Rights to Clinical-Stage ...  -  ‎Nov 5, 2009‎
Genetic Engineering News (press release)...the CD19 surface antigen, which is specific for B cells. The therapy has orphan drug designation for chronic lymphocytic leukemia and mantle cell lymphoma.

Trubion CEO steps down  -  ‎Nov 16, 2009‎
TechFlash (blog)The money-losing company also recently signed a strategic partnership with Facet Biotech for the possible treatment of chronic lymphocytic leukemia.

New bill to aid vets hurt by Agent Orange - by land & sea  -  ‎Oct 28, 2009‎
New York Daily News...a flight operator on the USS Intrepid who last year was diagnosed with chronic lymphocytic leukemia (CLL), an incurable form of cancer. ...

Genmab/GlaxoSmithKline: first approval for Arzerra  -  ‎Oct 28, 2009‎
Trading Markets (press release)The decision was based on a pivotal study involving 225 chronic lymphocytic leukemia (CLL) patients who were refractory to both fludarabine and Campath ...

Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research ...  -  ‎Oct 30, 2009‎
Medical News Today (press release)Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are the same disease with slightly different manifestations. ...

Villager is inspiration for team preparing for marathon  -  ‎Nov 1, 2009‎
Villages Daily Sun...throughout her ordeal — was diagnosed in May 1999, when blood tests from a routine doctor's visit showed she had chronic lymphocytic leukemia, or CLL. ...

More Than 200 Abstracts Evaluating Celgene Products across a Range of ...  -  ‎Nov 11, 2009‎
WELT ONLINE...results in indications such as multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia and myelodysplastic syndromes.

Facet Biotech Reports Third Quarter 2009 Financial Results  -  ‎Nov 4, 2009‎
CNNMoney.com (press release)...a CD37-directed small modular immunopharmaceutical protein therapeutic in phase 1 clinical trials for chronic lymphocytic leukemia. ...

Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced ...  -  ‎Nov 5, 2009‎
ReutersAbout TREANDA TREANDA, a novel chemotherapy, was approved by the FDA for the treatment of chronic lymphocytic leukemia in March 2008. ...

Yeastward Ho! Alder's Antibody Method Nets Jumbo BMS Deal  -  ‎Nov 11, 2009‎
Therapeutics Daily (press release) (registration)Arzerra, not yet approved in RA, recently won the FDA's nod in chronic lymphocytic leukemia, and is made by Genmab partner GlaxoSmithKline plc, of London. ...

Micromet terminates agreement with MedImmune for MT103 (MEDI-538)  -  ‎Nov 9, 2009‎
Trading Markets (press release)...phase I studies of MT103 in non- Hodgkin lymphoma (NHL) and plans to initiate a phase I study in chronic lymphocytic leukemia (CLL) later this year. ...

CombiMatrix Reports Q3 Sales Decline, Considers Strategic Options for Future  -  ‎Nov 12, 2009‎
GenomeWeb Daily News...the ATScan test for identifying copy number variants associated with autism spectrum disorder; the HemeScan test for chronic lymphocytic leukemia; ...

Making Sense of Antisense and Its Rebound Potential  -  ‎Nov 13, 2009‎
Genetic Engineering News (press release)The drug has been in clinical trials for melanoma and chronic lymphocytic leukemia (CLL) since 1995 in the US, Europe, and Australia and has yet to win ...

Athlete, husband, volunteer Wald passes away  -  ‎Oct 28, 2009‎
The Daily PlanetHe fought a long, valiant battle against Chronic Lymphocytic Leukemia. He was born in Brookline, Mass., on July 21, 1935. He was the son of the late Harold ...

HealthCor slams Biogen CEO for outsize pay package  -  ‎Nov 20, 2009‎
Forbes...programs for lumiliximab, its experimental treatment for chronic lymphocytic leukemia, and galiximab, for follicular lymphoma, another blood cancer. ...

Report Highlights Cancer Advances  -  ‎Nov 9, 2009‎
MedPage TodayFostamatinib, which inhibits the enzyme Syk kinase, achieved measurable responses in 5% of patients with chronic lymphocytic leukemia, 21% of patients with ...

Genmab to Sell Manufacturing Facility and Cut 300 Jobs  -  ‎Nov 5, 2009‎
Genetic Engineering News (press release)...human CD20 antibody, Arzerra™, as a treatment for patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. ...

Genmab Still Cutting: 300 Jobs and Manufacturing Next to Go  -  ‎Nov 6, 2009‎
Therapeutics Daily (press release) (registration)Genmab's lead antibody, Arzerra (ofatumumab) - which last week won its first approval in chronic lymphocytic leukemia and also is being studied for ...

Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson ...  -  ‎Nov 5, 2009‎
Pharmaceutical Technology Magazine...from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. ...

Preliminary Data on Genta's Melanoma Drug Sends Firm Crashing  -  ‎Oct 29, 2009‎
Genetic Engineering News (press release)Genta is also studying Genasense in chronic lymphocytic leukemia (CLL; Phase III) and non-Hodgkin's lymphoma (Phase II). The drug candidate inhibits ...

Progenika Inks Companion-Dx Deal with AMT, Service Pact with ARUP Labs  -  ‎Nov 3, 2009‎
GenomeWeb Daily News...chronic transfusions, such as chronic lymphocytic leukemia, autoimmune hemolytic anemia, Hodgkin's lymphoma, sickle cell disease, and thalassemia. ...

Rituxan®-Fludara® Highly Effective for Extranodal MALT B-cell Lymphomas  -  ‎Nov 9, 2009‎
Cancer ConsultantsMarginal-zone lymphomas are included in the “low grade? category, and treatments are similar to those for chronic lymphocytic leukemia (CLL) and follicular ...

Genmab to Present Data from Multiple Studies at ASH  -  ‎Nov 11, 2009‎
PharmaLive (press release) (subscription)Ofatumumab is approved in the US for treatment of chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. Ofatumumab is not approved ...

Antibody receptor identity supposedly discovered  -  ‎Nov 21, 2009‎
HealthJockey.comTo recognize the true FCMR gene, the UAB experts applied chronic lymphocytic leukemia cells as a foundation of this gene, because such leukemia cells are ...

Clinic Roundup  -  ‎Nov 9, 2009‎
Therapeutics Daily (press release) (registration)...anti-CD20 antibody, is being co-developed with London-based GlaxoSmithKline plc and recently gained approval in refractory chronic lymphocytic leukemia. ...

Unlocking the secrets of early immune response  -  ‎Oct 28, 2009‎
R & D MagazineTo identify the FcμR gene, researchers constructed cDNA libraries from chronic lymphocytic leukemia cells, known to express high levels of IgM receptors, ...

BRIEF-Genentech and Biogen get FDA complete response for Rituxan in chronic ...  -  ‎Nov 18, 2009‎
Interactive InvestorInteractive Investor Trading Limited, trading as "Interactive Investor", is authorised and regulated by the Financial Services Authority. ...

Celgene and Innate Collaborate on Trial Combining Their Multiple Myeloma Therapies  -  ‎Nov 18, 2009‎
Genetic Engineering News (press release)Additionally, the drug is in Phase III trials against chronic lymphocytic leukemia and non-Hodgkin's lymphoma as well as Phase II development against solid ...



Background information on Chronic Lymphocytic Leukemia [When available]

Chronic lymphocytic leukemia, or CLL, is a cancer in which too many lymphocytes (a type of white blood cells) are produced.

CLL has two subtypes: T-cell and B-cell. The latter (B-cell) is the most common form (about 95%) and shows up mainly in the bone marrow and blood. B-cell CLL is closely related to (and some may consider it the same as) a disease called Small-cell lymphocytic lymphoma (SLL), a type of non-Hodgkin's lymphoma expressed primarily in the lymph nodes.

CLL is the most-diagnosed form of leukemia in adults. Men are twice as likely to develop CLL as women, however the key risk factor is age: over 75% of new cases are diagnosed in patients over age 50. About 7300 new cases of CLL are diagnosed in the U.S. each year.

Search the web for more resources on Chronic Lymphocytic Leukemia



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy